Dulai et al reported a clinical decision support tool (CSDT) for predicting the response of a patient with ulcerative colitis to therapy with vedolizumab. The authors are from multiple institutions in the United States and Canada.
Patient selection: ulcerative colitis
Outcome: steroid-free remission at 26 weeks
Parameters:
(1) prior TNF antagonist exposure
(2) disease duration in years
(3) baseline endoscopy activity (choices moderate or severe)
(4) baseline serum albumin in g/L
Parameter
Finding
Points
prior TNF antagonist therapy
no
0.2820
yes
0
disease duration
< 2 years
0
>= 2 years
0.2622
baseline endoscopy activity
moderate
0.1847
severe
0
baseline serum albumin
0.0647 * (albumin)
value of Y =
= SUM(points for all of the parameters) - 3.7038
probability of response to vedolizumab =
= 1 / (1 + EXP((-1) * Y))
Performance:
• The area under the ROC curve is 0.65.
To read more or access our algorithms and calculators, please log in or register.
